Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTXHYV6)

DTT Name Voltage-gated L-type calcium channel (L-CaC)
Synonyms L-type voltage-dependent Ca(2+) channel; L-type Ca2+ channel; L-type Ca(2+) channel
Gene Name L-CaC
DTT Type
Successful target
 [1]
BioChemical Class
Voltage-gated ion channel
UniProt ID
NOUNIPROTAC
TTD ID
T82266

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DTT
5 Approved Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Clevidipine butyrate DMW4M97 Hypertension BA00-BA04 Approved [2]
Epalrestat DM5OGK0 Diabetic neuropathy 8C0Z Approved [3]
Nifedipine DMSVOZT Angina pectoris BA40 Approved [4]
Otilonium bromide DM05968 Gastric motility disorder DA21 Approved [1]
Levamlodipine DM92S6N Hypertension BA00-BA04 Phase 4 [5]
------------------------------------------------------------------------------------
5 Clinical Trial Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cilnidipine DM1975O High blood pressure BA00 Phase 3 [6]
Pinaverium bromide DM7OSHC Irritable bowel syndrome DD91.0 Phase 3 [1]
MEM-1003 DMYZU6G Bipolar disorder 6A60 Phase 2a [7]
BAY-Y-5959 DMLO18H Cardiovascular disease BA00-BE2Z Phase 2 [8]
Gallopamil DMXBR27 Asthma CA23 Phase 2 [9]
------------------------------------------------------------------------------------
1 Discontinued Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Furnidipine DME94QF Nerve injury ND56.4 Discontinued in Phase 3 [10]
------------------------------------------------------------------------------------
20 Investigative Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ajinomoto 1 DMHMVOI Pain MG30-MG3Z Investigative [3]
Ajinomoto 2 DMZE45V Pain MG30-MG3Z Investigative [3]
Ajinomoto 3 DMG12AE Pain MG30-MG3Z Investigative [3]
Bay K 8644 DMRWSGO Discovery agent N.A. Investigative [11]
Dihydropyridines DM0W64U Discovery agent N.A. Investigative [12]
Euro-Celtique 1 DMO3AZ6 Pain MG30-MG3Z Investigative [3]
Euro-Celtique 2 DMJH4BF Pain MG30-MG3Z Investigative [3]
Euro-Celtique 3 DM8VI3T Pain MG30-MG3Z Investigative [3]
Euro-Celtique 4 DMO4CEL Pain MG30-MG3Z Investigative [3]
Neuromed 2 DMSJ6T1 Pain MG30-MG3Z Investigative [3]
Neuromed 5 DMXKT45 Pain MG30-MG3Z Investigative [3]
Ono 1 DMSWI4D Pain MG30-MG3Z Investigative [3]
Ono 3 DMCG6H8 Pain MG30-MG3Z Investigative [3]
Parke-Davis 1 DMVI8R2 Pain MG30-MG3Z Investigative [3]
Parke-Davis 9 DMMQY42 Pain MG30-MG3Z Investigative [3]
PD173212 DMRBKW6 Pain MG30-MG3Z Investigative [3]
PD176078 DM6XHUZ Pain MG30-MG3Z Investigative [3]
S 202 791 DMGEHNX Discovery agent N.A. Investigative [11]
SQ32,910 DML6SIE Discovery agent N.A. Investigative [11]
[3H](-)devapamil DM0KGHP Discovery agent N.A. Investigative [9]
------------------------------------------------------------------------------------
⏷ Show the Full List of 20 Investigative Drug(s)

References

1 Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313.
2 Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
3 Recent updates of N-type calcium channel blockers with therapeutic potential for neuropathic pain and stroke. Curr Top Med Chem. 2009;9(4):377-95.
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
5 Effects of (S)-amlodipine and (R)-amlodipine on L-type calcium channel current of rat ventricular myocytes and cytosolic calcium of aortic smooth muscle cells. Pharmazie. 2008 Jun;63(6):470-4.
6 N- and L-type calcium channel antagonist improves glomerular dynamics, reverses severe nephrosclerosis, and inhibits apoptosis and proliferation in an l-NAME/SHR model. J Hypertens. 2002 May;20(5):993-1000.
7 Efficacy of MEM 1003, a novel calcium channel blocker, in delay and trace eyeblink conditioning in older rabbits. Neurobiol Aging. 2007 May;28(5):766-73.
8 Hemodynamic effects of a calcium channel promoter, BAY y 5959, are preserved after chronic administration in ischemic heart failure in conscious dogs. J Pharmacol Exp Ther. 1998 Aug;286(2):760-6.
9 Role of apoptosis in the kidney after reperfusion. Orv Hetil. 2008 Feb 17;149(7):305-15.
10 Q-type Ca2+ channels are located closer to secretory sites than L-type channels: functional evidence in chromaffin cells. Pflugers Arch. 1998 Mar;435(4):472-8.
11 Molecular determinants of drug binding and action on L-type calcium channels. Annu Rev Pharmacol Toxicol. 1997;37:361-96.
12 Pharmacology of N-type Ca2+ channels distributed in cardiovascular system (Review). Int J Mol Med. 1999 May;3(5):455-66.